| 摘要: |
| 习近平总书记关于新质生产力的一系列重要论述、重大部署,为药品监管高质量发展提供了基本遵循。本文主要探讨我国药品监管新质生产力的发展路径。当前我国药品创新在部分赛道已经实现跟跑向并跑转变,医药产业结构更新加快,药品监管对象的新质生产力特点正逐渐展现。推动药品监管新质生产力的主要因素在于劳动者和劳动工具即监管人员和监管工具。存在的问题包括:高素质药品监管人才缺口大,传统药品监管工具难以满足需求,尚未完全建立药品智慧监管模式等。据此,提出培养新时代药品监管科学创新人才,加快药品监管工具创新,推动药品监管模式创新等具体措施建议,以期加快发展药品监管新质生产力,助力药品监管高质量发展。 |
| 关键词: 新质生产力 药品监管 创新 |
| DOI:10.13506/j.cnki.jpr.2025.02.008 |
| 基金项目:国家药品监督管理局药品监管科学体系建设重点项目(No.RS2024G002) |
|
Publication Date:February 25, 2025
|
|
| Study on the path of new quality productivity to promote high quality development of pharmaceutical regulation |
| YUAN Yanfang |
| (National Medical Products Administration Institute of Executive Development,Beijing 100073, China) |
| Abstract: |
| General Secretary Xi Jinping's series of important expositions and major deployments on new quality productivity have provided a basic guideline for the high-quality development of Drug regulation. This paper focuses on the development path of new quality productivity in China's drug regulation. At present, China's drug innovation in some tracks has realized the change from running behind to running in parallel, and the renewal of the structure of the pharmaceutical industry has accelerated, hence the characteristics of the new quality productivity of the drug regulatory object are gradually unfolding. The main factors driving the new quality productivity of drug regulation are laborers and labor tools, and that means the regulatory personnel and regulatory tools. Existing problems include a large shortage of high-quality regulatory personnel; traditional regulatory tools are difficult to meet the demand; and a smart regulatory model has not yet been fully established. Accordingly, specific measures are proposed to cultivate innovative talents in regulatory science in the new era, accelerate the innovation of drug regulatory tools and promote the innovation of drug regulatory models, with a view to accelerating the development of new quality productivity in drug regulation and contributing to the high-quality development of drug regulation. |
| Key words: New quality productivity Drug regulation Innovation |